Catheter Precision's VIVO is Now Eligible for National The National Health System England Grants VIVO™ Additional Reimbursement
FORT MILL, SC / ACCESSWIRE / October 12, 2023 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announces that its VIVO 3D mapping system has been granted national reimbursement in the UK after inclusion in the High-Coast Tariff Excluded Devices (HCTED). VIVO enables physicians to identify the origin of ventricular arrhythmias pre-procedure, streamlining workflow and reducing procedure time.
Dr. Moloy Das consultant Cardiologist & Electrophysiologist at the Freeman Hospital located in Newcastle, UK says, "I am delighted that VIVO is now available via the HCTED/Specialized Services Devices program. This will allow greater access to this technology for patients who would benefit from its use in their procedure."
HCTED is a nationwide purchase and supply system for the National Health Service England (NHS England) designed to pay for products that qualify for separate payment from the national budget for medical procedures. Hospitals are now able to bill the cost of the of the single use component directly to the NHS.
Patricia Kennedy, Chief Commercial Officer said, "Over the last couple of years we have created a footprint with several hospitals utilizing our VIVO technology. Now that VIVO has been accepted to HCTED, we believe this will further support the adoption of the VIVO technology and allow for greater market access and expanded reimbursement."
https://www.accesswire.com/792220/catheter-precisions-vivo-is-now-eligible-for-national-reimbursement-in-the-uk